FDA closes loophole letting drug makers delay generic competition

What it does

This bill amends the FDA's citizen petition process to speed up generic drug approvals by making it harder for brand-name drug makers to use petitions as delay tactics. It requires petitions to be filed within 180 days of learning the relevant information, mandates that all arguments be disclosed upfront, and gives the FDA explicit factors to identify petitions filed primarily to delay competitors' applications. Courts must dismiss lawsuits that skip the petition process or file too late.

Why we flagged it

The bill's core mechanism is procedural reform of the FDA citizen petition process to eliminate delay tactics and accelerate generic drug market entry. It is fundamentally a pro-competition, pro-consumer measure targeting a known abuse of administrative process.

What the text implies

• Brand-name manufacturers lose a key regulatory tool for extending market exclusivity; this may accelerate generic competition timelines by months or years per drug.
• The 180-day filing window creates a hard deadline that may force brand-name makers to decide early whether to challenge a generic application, reducing their strategic flexibility.
• The requirement to disclose all arguments upfront prevents incremental or serial petitions that raise new objections after initial FDA responses, closing a known loophole.
• Courts gain explicit authority to dismiss lawsuits that bypass the FDA petition process, strengthening administrative exhaustion doctrine and reducing litigation risk for generic applicants.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people benefit from faster generic drug access and lower prices. The bill directly targets a known delay tactic used by brand-name manufacturers to extend monopoly periods and block cheaper alternatives, while preserving legitimate safety and efficacy challenges through the FDA's administrative process.

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• pharmacy benefit managers
• health insurers
• consumers purchasing generic medications

Named in the bill

FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Section 505(q), Public Health Service Act Section 351(k), brand-name pharmaceutical manufacturers, generic drug manufacturers, biosimilar manufacturers

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Oct 16, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Oct 16, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

23 lobbying clients named this bill on 23 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $16,609,347 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Jeanne Shaheen, the sponsor, reported $-12,050 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Blue Cross and Blue Shield Association — $990,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.